| Autor: |
SONG PENG, WENHONG DONG, QIANGQIANG CHU, JIA MENG, HAITAO YANG, YINGYING DU, YU SUN, HOFFMAN, ROBERT M. |
| Předmět: |
|
| Zdroj: |
In Vivo; May/Jun2021, Vol. 35 Issue 3, p1437-1441, 5p |
| Abstrakt: |
Background/Aim: Small-cell lung cancer (SCLC) is a recalcitrant disease with liver and other metastasis. The present study evaluated the efficacy of the traditional Chinese medicine Brucea javanica oil (BJO) combined with anlotinib, a multi-tyrosine kinase inhibitor with anti-angiogenic activity, on a nude-mouse model of SCLC liver metastasis. Materials and Methods: The mouse model was established by injecting NCI-H446 cells (1x106) in Matrigel (20 fl) into the upper liver lobe. All animals were randomized and assigned to three groups: Control (n=8); anlotinib alone (n=8; 3 mg/kg, qdx14+7-day interval with two cycles, oral); anlotinib plus BJO (n=8; 3 mg/kg anlotinib qdx 14+7-day interval with two cycles, orally; BJO: 1 g/kg, qdx6 weeks, orally). Body weight was determined every week. Six weeks after initial treatment, tumors were collected for analysis of angiogenesis using immunohistochemistry. Results: The combination of anlotinib and BJO significantly inhibited growth of SCLC liver metastases and angiogenesis more than anlotinib monotherapy (p=0.043). In addition, BJO alleviated body-weight loss associated with anlotinib therapy, including general mouse condition. Conclusion: The results of the present study indicate that the combination of anlotinib with BJO is promisingly active against liver metastases of SCLC, and has clinical potential. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
